<i id='E7CEAB6A1F'><strike id='E7CEAB6A1F'><tt id='E7CEAB6A1F'><pre id='E7CEAB6A1F'></pre></tt></strike></i> 
EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
advertisement
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
Medicare details structure of new drug price negotiation program 
FDA advisers vote against ALS treatment from BrainStorm 
Alkermes shareholders re 
Covid vaccines: Private market messier than government rollout 
ChatGPT in medicine: STAT answers readers' burning questions 
Nevada Republican Sam Brown launching another Senate bid, teeing up marquee race 
Psychedelics group wrestles with new pharma identity 
The aspartame in Diet Coke probably isn’t giving you cancer 
Bright Health sells Medicare Advantage business to Molina 
Presidential fundraising highlights so far: Trump brings in more than DeSantis 
Medicare proposal to cover medical devices draws a mixed reaction 
‘Insidious 5’ topples 'Indiana Jones' before ‘Mission: Impossible’ launches 
Medical records are filled with copy 
Intercept Pharmaceuticals sells itself for less than $1 billion 
Drug repurposing or repositioning? The language matters 
